Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.

Martin Stanulla, MD, Elke Schaeffeler, PhD, Anja Moericke, MD, Gunnar Cario, MD, Michel Eichelbaum, MD, Hansjoerg Riehm, MD, Karl Welte, MD, Martin Schrappe, MD, Matthias Schwab, MD

Blood (2006) 108 (11): 150.

https://doi.org/10.1182/blood.V108.11.150.150

Published: 2006

Journal Articles

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Valentino Conter, Maria Grazia Valsecchi, Daniela Silvestri, Myriam Campbell, Eduardo A. Dibar, Edina Magyarosy, Helmut Gadner, Jan Stary, Yves Benoit, Hansjoerg Riehm, Giuseppe Masera, Martin Schrappe

Blood (2005) 106 (11): 11.

https://doi.org/10.1182/blood.V106.11.11.11

Published: 2005

Journal Articles

Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.

Olga Wachowski, MD, Martin Zimmermann, PhD, Birgit Burkhardt, MD, Olaf Determann, MD, Ulrike Meyer, Peter Kaatsch, PhD, Georg Mann, MD, Reza Parwaresch, MD, Hansjoerg Riehm, MD, Martin Schrappe, MD, Alfred Reiter, MD

Blood (2005) 106 (11): 232.

https://doi.org/10.1182/blood.V106.11.232.232

Published: 2005

Journal Articles

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

Wilhelm Woessmann, Kathrin Seidemann, Georg Mann, Martin Zimmermann, Birgit Burkhardt, Ilske Oschlies, Wolf-Dieter Ludwig, Thomas Klingebiel, Norbert Graf, Bernd Gruhn, Heribert Juergens, Felix Niggli, Reza Parwaresch, Helmut Gadner, Hansjoerg Riehm, Martin Schrappe, Alfred Reiter, for the BFM Group

Blood (2005) 105 (3): 948–958.

https://doi.org/10.1182/blood-2004-03-0973

Published: 2005

Journal Articles

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Marja J. Willemse, Taku Seriu, Klaudia Hettinger, Elisabetta d'Aniello, Wim C. J. Hop, E. Renate Panzer-Grümayer, Andrea Biondi, Martin Schrappe, Willem A. Kamps, Guiseppe Masera, Helmut Gadner, Hansjoerg Riehm, Claus R. Bartram, Jacques J. M. van Dongen

Blood (2002) 99 (12): 4386–4393.

https://doi.org/10.1182/blood.V99.12.4386

Published: 2002

NARROW

Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Email alerts

ASH Publications

American Society of Hematology

Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.

Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.

Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only